مشخصات کتاب

Anti-Inflammatory Drugs

ویرایش: 1 
نویسندگان: R. J. Gryglewski (auth.),  Dr. John R. Vane,  Dr. Sergio H. Ferreira (eds.)  
سری: Handbook of Experimental Pharmacology 50 / 2 : Inflammation 
ISBN (شابک) : 9783642668937, 9783642668913 
ناشر: Springer-Verlag Berlin Heidelberg 
سال نشر: 1979 
تعداد صفحات: 981 
زبان: English 
فرمت فایل : PDF (درصورت درخواست کاربر به PDF، EPUB یا AZW3 تبدیل می شود) 
حجم فایل: 24 مگابایت 

کلمات کلیدی مربوط به کتاب داروهای ضد التهاب: پزشکی / بهداشت عمومی، عمومی، داروسازی

در صورت تبدیل فایل کتاب Anti-Inflammatory Drugs به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.

توجه داشته باشید کتاب داروهای ضد التهاب نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.

توضیحاتی درمورد کتاب به خارجی

Screening and Toxicity of Anti-Inflammatory Drugs.- 19 Screening and Assessment of the Potency of Anti-Inflammatory Drugs in vitro.- A. Introduction.- B. Interaction With Non-Enzymic Proteins.- I. Binding to Plasma Proteins.- 1. Displacement Reactions.- 2. Disulphide Interchange Reactions.- 3. Protection Against Protein Denaturation.- 4. Fibrinolytic Activity.- II. Interaction With Biological Membranes.- 1. Effects on Erythrocyte Membrane.- 2. Effects on Lysosomal Membrane.- 3. Cytotoxic Properties.- 4. Effects on Leucocyte Migration.- C. Interaction With Enzymic Proteins.- I. General Considerations.- II. Interaction With Enzymes Involved in Carbohydrate, Protein, and Nucleic Acid Metabolism.- 1. Carbohydrate, Protein, and Amino Acid Metabolism.- 2. Nucleic Acid and Nucleotide Metabolism.- III. Inhibition of Prostaglandin Synthetase.- 1. Prostaglandin Synthetase System.- 2. Assay of Prostaglandin Synthetase Activity.- 3. Prostaglandin Synthetase Inhibitors.- 4. Inhibition of Platelet Aggregation.- 5. Effects on Smooth Muscle.- D. Conclusions.- References.- 20 Inhibition of Erythema and Local Hyperthermia.- A. Introduction.- B. Ultraviolet (UV) Light and the Erythematous Response.- C. Instrumentation.- I. Light Sources for Induction of Erythema.- II. Measurement of Erythema and Local Hyperthermia.- 1. Erythema.- 2. Skin Temperature.- D. Procedures.- I. Erythema.- 1. UV-Induced.- 2. Thurfyl Nicotinate-Induced.- 3. Miscellaneous Procedures for Producing Erythema.- II. Local Hyperthermia.- 1. Local Hyperthermia in Paws of Rats Injected With Irritants.- 2. Local Hyperthermia in UV-Irradiated Skin.- E. Inhibition of Erythema and Local Hyperthermia.- I. UV-Induced Erythema.- 1. Systemic Administration of Drugs.- 2. Topically or Intradermally.- II. Tetrahydrofurfuryl Nicotinate (THFN) Erythema.- III. Other Erythemas.- IV. Local Hyperthermia.- F. Conclusion.- References.- 21 Oedema and Increased Vascular Permeability.- A. General Principles of Assays.- I. Statistical Considerations in Assay Work.- 1. Relationship of Dose to Effect.- 2. Definition of ED50.- 3. Confidence Limits.- 4. Coefficent of Variation.- 5. The g Value.- 6. The Lambda Value, ?.- 7. Errors of Types I and II.- B. Methods for Producing and Measuring Oedema and Increased Vascular Permeability.- I. Oedemas of the Rat’s Paw.- 1. Measurement.- 2. Agents Causing Paw Oedema; Characteristics of Oedemas Caused by Several Agents.- II. Increased Vascular Permeability.- III. Oedema in the Pleural Space.- C. Conclusion.- References.- 22 Short-Term Drug Control of Crystal-Induced Inflammation.- A. Historical Aspects.- B. Mechanism of Crystal-Induced Inflammation.- I. Phagocytosis.- II. Membranolysis.- III. Inflammatory Mediators.- IV. Chemotactic Factors.- C. Experimental Models.- I. Animal.- II. Man.- D. Therapy of Acute Attacks of Gout and Pseudogout.- I. Gout.- II. Pseudogout.- E. Summary.- References.- 23 Experimental Models of Arthritis in Animals as Screening Tests for Drugs to Treat Arthritis in Man.- A. Introduction.- B. Advantages and Disadvantages of Models of Arthritis—Comparison With Acute Models.- C. Adjuvant-Induced Arthritis.- I. First Observation. First Use as a Screen for Anti-Inflammatory/ Antirheumatic Drugs.- II. Production.- 1. Adjuvant.- 2. Route of Injection.- 3. Species Variation and Strain Variation.- 4. Time Course of the Disease.- III. Aetiology.- 1. Role of Lymphatic System.- 2. Immunological Mechanisms.- 3. Histology.- 4. Lysosomal Enzymes.- IV. Assessment.- 1. Physical Assessment—Gross Measurements.- 2. Physiological/Functional Parameters.- 3. Biochemical Parameters.- 4. Period of Dosing of Compounds.- V. Effect of Drugs.- 1. Non-Steroid Anti-Inflammatory Drugs.- 2. Steroid Anti-Inflammatory Drugs.- 3. Gold, Chloroquine, and Penicillamine.- 4. Immunosuppressant Drugs.- 5. Antilymphocytic Serum, Antigens.- 6. Non-Specific Inhibition.- 7. The Effect of Adjuvant Arthritis on Drugs.- D. Arthritis Produced by Intra-Articular Injection of Antigens and Antibodies.- E. Arthritis Produced by Intra-Articular Injection of Lysosome Labilisers.- F. Arthritis Induced by Infectious Agents.- E. Conclusions.- References.- 24 Antagonism of Bradykinin Bronchoconstriction by Anti-Inflammatory Drugs.- A. Introduction.- B. Production of Kinins and Other Mediators of Anaphylaxis in the Lungs.- I. In vitro.- II. In vivo.- III. Release of Catecholamines in vivo.- C. Action of Bradykinin on Lung Function.- I. Bronchial Smooth Muscle in vitro and in vivo.- II. Pulmonary Circulation.- D. Release of Prostaglandins and Precursors From Lungs by Bradykinin.- E. Actions of Prostaglandins in the Lungs.- I. Bronchial Smooth Muscle.- F. Interaction of Bradykinin With Prostaglandins in the Lungs.- I. As a Mediator.- II. As a Potentiator.- III. As a Mediator of Vascular Leakage.- G. Metabolism of Kinins in the Pulmonary Circulation.- H. Inhibition of Bronchoconstriction by Anti-Inflammatory Acids.- I. In vivo and in vitro Studies.- II. Comparison With Other Bronchoconstrictor Agents.- I. Possible Actions and Interactions of Kinins and Prostaglandins in Asthma.- J. Summary and Conclusions.- References.- 25 Interference of Anti-Inflammatory Drugs With Hypotension.- A. Interference of Non-Steroidal Anti-Inflammatory Drugs With Hypotensive Effects of Potential Inflammatory Mediators.- I. Kinin Peptides.- II. Prostaglandins.- B. Interference by Non-Steroidal Anti-Inflammatory Drugs With the Hypotensive Effects of Agents That Release Potential Inflammatory Mediators.- I. Proteolytic Enzymes.- 1. Kininogenases.- 2. Thrombin.- 3. Other Proteolytic Enzymes.- II. Inhibition of Hypotension Due to Substances That Activate Plasma Kininogenase.- 1. Carrageenin.- 2. Other Activators of Plasma Kininogenase.- III. Phospholipase A2.- C. Interference of Anti-Inflammatory Drugs With Hypotensive Responses to Lipid Derivatives.- I. Effects of Arachidonic Acid on Arterial Blood Pressure.- 1. Mechanism of Action of Arachidonic Acid on Blood Pressure.- II. Effects of Fatty Acids Other Than Prostaglandin Precursors.- III. Slow Reacting Substance C.- 1. Mechanism of Action of Slow Reacting Substance C.- D. Interference of Non-Steroidal Anti-Inflammatory Agents With Effects of Miscellaneous Agents.- I. Adenosine Nucleotides.- II. Collagen.- III. Anaphylatoxin.- IV. Depressor Active Substance (DAS).- V. Platelet Clumping Substance.- VI. Barium Sulphate and Other Particulate Materials.- E. Interference of Non-Steroidal Anti-Inflammatory Agents With Hypotension in Endotoxin Shock.- I. Dogs.- II. Cats.- III. Other Animal Species.- F. Mechanism of Action of Hypotensive Agents Liable to Inhibition by Non-Steroid Anti-Inflammatory Drugs.- I. Structure-Activity Correlations.- 1. Thiol and Anti-Oxidant Compounds.- II. Stereospecificity.- III. Mechanism of Action of Hypotensive Agents Subject to Inhibition by Non-Steroidal Anti-Inflammatory Drugs.- 1. Bradykinin.- 2. Collagen.- 3. Carrageenin.- 4. Adenosine Nucleotides.- IV. Conclusions.- 1. Relevance of Hypotensive Responses to Inflammation and to Study of Inflammatory Events.- 2. Multisequential Activation and Acute Hypotensive Responses: Prospects of Research.- References.- 26 Antagonism of Pain and Hyperalgesia.- A. Introduction.- I. Terminology.- II. Historical Introduction to Analgesic Testing in Hyperalgesic Animals.- B. Non-Hyperalgesic Mild Analgesic Assays.- I. Stretching Tests.- C. Assessment of Mild Analgesia in Humans.- I. Clinical Avaluation of Mild Analgesic Agents.- D. Conclusion.- References.- 27 Inhibition of Cell Migration in vivo and Granuloma Formation.- A. General Introduction.- I. Mechanisms of Cell Migration.- II. The Sequence of Cell Migration.- III. Fate of Emigrated Cells.- 1. Polymorphs.- 2. Mononuclear Cells.- IV. Granuloma Formation and Evolution.- B. Models for Leucocyte Emigration in vivo.- I. Generalities.- II. Histological Method.- III. Cell Collection From Cavities.- 1. Natural Cavities.- 2. Artificial Cavities.- IV. Cell Collection From Early Granulomata.- V. Cell Labelling.- C. Models for Granuloma Formation in vivo.- I. Cotton-Pellet Granuloma.- II. Granuloma Pouch.- III. Carrageenin Granuloma.- IV. Plastic Ring Granuloma.- V. Filter Paper Granuloma.- D. Inhibition of Cell Migration in vivo.- I. Steroids.- 1. Neutrophils.- 2. Mononuclear Cells.- II. Non-Steroid Anti-Inflammatory Drugs.- III. Immunosuppressive Agents.- IV. Endogenous Substances.- E. Inhibition of Granuloma Formation.- I. Steroid Anti-Inflammatory Drugs.- II. Non-Steroid Anti-Inflammatory Drugs.- III. Immunosuppressive Agents.- IV. Endogenous Substances.- F. Conclusions.- References.- 28 Inhibition of Fever.- A. Introduction.- B. Pathogenesis of Fever.- I. Exogenous and Endogenous Pyrogen.- II. Site of Action of Pyrogens.- III. Mechanism of Action of Pyrogens.- 1. Change in Set-Point or Gain?.- 2. Role of Prostaglandins.- 3. Role of Monoamines and Cyclic-AMP.- 4. Ionic Mechanisms in Fever.- C. Antipyretics.- I. Possible Sites of Action of Antipyretics.- 1. Inactivation of Bacterial Pyrogen (Site I).- 2. Inhibition of Endogenous Pyrogen Production or Release (Site II).- 3. Inhibition of Endogenous Pyrogen Activity (Site III).- 4. Access of Endogenous Pyrogen to the Central Nervous System (Site IV).- 5. Hypothalamic Thermoregulatory Centres (Site V).- 6. Suppression of Heat Production (Site VI).- II. Possible Mechanisms of Antipyretic Action.- 1. Inhibition of Prostaglandin Synthesis/Release.- 2. Competitive Antagonism Between Pyrogens and Antipyretics for a Receptor Site.- 3. Alteration in the Activity of Neurones in the Hypothalamus.- III. Antipyresis.- D. Inhibition of Fever by Other Means.- I. Increased Heat Loss.- II. Monoamine Blockade and Depletion.- III. Cholinergic Blockade.- E. Conclusion.- References.- 29 Evaluation of the Toxicity of Anti-Inflammatory Drugs.- A. Introduction.- I. Historical Overview.- B. Evaluation of Toxicity in Man.- I. Gastrointestinal Tract.- II. Central Nervous System.- III. Dermatological Disorders.- IV. Haematopoietic System.- V. Ocular Disturbances.- VI. Renal Side Effects.- VII. Miscellaneous Side Effects.- C. Methods Used to Evaluate Toxicity in Animals.- I. Gastrointestinal.- II. Kidney.- III. Haematopoietic System.- IV. Liver.- V. Skin.- VI. Eye.- VII. Central Nervous System.- D. Correlation of Experimental Models With Clinical Toxicity.- I. Non-Steroid Anti-Inflammatory Drugs.- 1. Salicylates.- 2. Indomethacin.- 3. Phenylbutazone.- 4. Arylalkanoic Acids.- 5. Gold.- II. Steroids.- E. Summary.- References.- Pharmacology of the Anti-Inflammatory Agents.- 30 Prostaglandin Synthetase Inhibitors I.- A. Introduction.- B. Inhibiton of Synthetase by Substrate Analogues and Fatty Acid Derivatives.- I. Unsaturated Fatty Acids.- II. Bicyclic Analogues.- C. Regulation of Enzymic Factors: Co-Factors, Stimulation, and Catabolism.- I. Regulation of Biosynthesis.- II. Catabolic Enzymes.- D. Inhibition by Non-Steroid Anti-Inflammatory Agents.- I. An Overview of Structure-Activity Relationship.- 1. Correlation of PG Syntheatase Inhibition With Anti-Inflammatory Action.- 2. General Structure-Activity Relationship.- II. Salicylates.- III. Indomethacin, Sulindac, and Congeners.- IV. Substituted Aryl Aliphatic Acids.- V. Fenamates.- VI. Other Acidic Anti-Inflammatory Agents.- VII. Non-Acidic Anti-Inflammatory Agents.- E. Effects of Corticosteroids.- F. Inhibition and Stimulation by Other Pharmacological Agents.- I. Anti-Arthritic and Related Compounds.- II. Psychotropic Drugs.- III. Sulphydryl Reagents and Derivatives.- IV. Hormones and Mediators.- V. Inactive Pharmacological Agents.- G. The Search for New Inhibitors.- I. Current Research Trend.- II. Biochemical and Physiological Specificity.- III. Pharmacodynamic and Metabolic Control.- IV. Multiple-Action Inhibitors.- V. Synthetic and Physicochemical Approaches.- H. Pharmacokinetics of Prostaglandin Synthetase Inhibitors.- I. Conclusion.- References.- 31 Mode of Action of Anti-Inflammatory Agents Which are Prostaglandin Synthetase Inhibitors.- A. Mediators and Inflammatory Responses.- B. Mechanism of Anti-Inflammatory Action.- I. Action on Step 1: Diminution of the Capability of Tissue Cells to Respond to Inflammatory Mediators.- 1. Increased Dilatation and Vascular Permeability.- 2. Pain and Hyperalgesia.- 3. Increased Fibroblast Proliferation and Secretion.- II. Action on Step 2: Pharmacological Receptor Antagonism.- III. Action on Step 3: Inhibition of Extracellular Enzymic Activities Which Generate Inflammatory Mediators or Cause Injury to Cell Membranes and/or Tissue Components.- IV. Action on Step 4: Inhibition of the Release of Intracellular Lytic Enzymes or Mediator-Genases or Stored Receptor-Mediators.- V. Action on Step 5: Inhibition of the Synthesis of Inflammatory Mediators.- 1. Prostaglandin Synthesis and Release.- 2. Prostaglandins and Inflammatory Signs and Symptoms.- 3. Correlation Between in vitro Inhibition of Prostaglandin Synthesis and Anti-Inflammatory Activity.- 4. Inhibition of Prostaglandin Synthesis in vivo and Inflammatory Signs and Symptoms.- VI. Action on Step 6: Inhibition of Cell Migration.- VII. Action on Step 7: Inhibition of the Generation of the Effective Inflammatory Trauma.- C. Side-Effects of Anti-Inflammatory Drugs Which are Prostaglandin Synthetase Inhibitors.- D. Theories and Theories.- References.- 32 Penicillamine and Drugs With a Specific Action in Rheumatoid Arthritis.- A. Classification of Antirheumatic Drugs.- B. Penicillamine.- I. Actions in Man.- II. Possible Mode of Action and Effects in Animal Models.- C. Gold Salts.- D. Chloroquine and Other Antimalarials.- E. Levamisole.- F. Other Imidazole Derivatives.- G. Immunosuppressives.- H. Alclofenac.- I. Steroids.- J. Summary.- References.- 33 Antagonists of Histamine, 5-Hydroxytryptamine and SRS—A.- A. Classification of Antihistamines.- B. Histamine H1 Antagonists: Structure-Activity Relationships.- C. Histamine H1 Antagonists: Inhibition of Responses to Histamine Involved in Inflammatory and Anaphylactic Reactions.- I. Guinea Pig.- II. Rat.- III. Rabbit.- IV. Mouse.- V. Man.- D. Histamine H2 Antagonists: Chemical Considerations.- E. Inhibition of Cardiovascular Responses to Histamine by H1 and H2 Antagonists.- F. Chemical and Pharmacological Classes of 5-Hydroxytryptamine Antagonists.- I. Chemical Classes.- II. “M” and “D” Receptors.- III. 201C;Musculotropic” and “Neurotropic” Receptors.- G. Antagonists of 5-Hydroxytryptamine: Inhibition of Responses to 5-HT Involved in Inflammatory and Anaphylactic Reactions.- I. Guinea Pig.- II. Rat.- III. Rabbit.- IV. Mouse.- V. Man.- H. Effects of Antagonists of Histamine (H1 Receptors) and 5-HT in Various Types of Inflammation.- I. Guinea Pig.- 1. Thermal and Ultraviolet Injury.- 2. Local Anaphylaxis.- 3. Systemic Anaphylaxis.- 4. Compound 48/80 and Polymyxin B.- 5. Bradykinin.- II Rat.- 1. Thermal and Ultraviolet Injury.- 2. Local Anaphylaxis.- 3. Systemic Anaphylaxis.- 4. Compound 48/80, Polymyxin, Dextran, and Egg White.- 5. Turpentine Pleurisy.- 6. Carrageenin Oedema.- 7. Croton Oil.- 8. Bradykinin.- III. Rabbit.- 1. Thermal Injury.- 2. Anaphylactic Reactions.- 3. Inflammation Associated With Bacterial Infections.- IV. Mouse.- 1. General Anaphylaxis.- 2. Cutaneous Anaphylaxis.- 3. Other Local Inflammatory Reactions.- 4. Systemic Reactions Involving Inflammation.- V. Man.- 1. Burns.- 2. Compound 48/80 and Polymyxin.- 3. Hypersensitivity States.- 4. Rheumatoid Arthritis and 5-HT Antagonists.- VI. Bovine Anaphylaxis.- I. Antagonists of SRS-A.- I. Non-Steroid Anti-Inflammatory Drugs.- II. Polyphloretin Phosphate (PPP).- III. FPL 55712.- IV. Hydratropic Acids.- J. Prospects for New Drugs.- References.- 34 Inhibitors of the Release of Anaphylatic Mediators.- A. Characteristics of Anti-Allergic Agents Discussed.- B. Cromoglycate and Similar Compounds.- I. Identification and Screening.- 1. The Passive Cutaneous Anaphylaxis Reaction (PCA) in Rats.- 2. Lung Anaphylaxis in vivo.- 3. Passive Peritoneal Anaphylaxis.- 4. Human Tissues in vitro.- 5. Rat Tissues in vitro.- II. Structure-Activity Relationships.- III. Anti-Allergic Properties.- 1. Tissue and Species Selectivity.- 2. Inhibition of Mast Cell Reactions Provoked by Stimuli Other Than Antigen-Antibody Interactions.- 3. Time Course Studies.- 4. Tachyphylaxis.- IV. Studies of the Mechanism of Anti-Allergic Action.- V. Other Pharmacological Effects.- VI. Pharmacokinetics.- C. Other Inhibitors of Mediator Release.- I. Isosteres of Theophylline.- 1. Structure-Activity Relationships.- 2. Anti-Allergic Properties.- II. Antihistamines and Histamine.- III. Diethylcarbamazine.- 1. Rat Peritoneal Cells in vivo.- 2. Lung Tissue.- 3. Human Leucocytes.- 4. Passive Cutaneous Anaphylaxis Reactions.- IV. Chlorphenesin.- D. Prospects for New Drugs.- References.- 35 Cytostats With Effects in Chronic Inflammation.- A. Introduction.- B. General Pharmacology of Cytostats Effective in Chronic Inflammation.- I. “Immunosuppressants”.- 1. Alkylating Agents.- 2. Anti-Metabolites.- II. Microtubular Inhibitors.- 1. Colchicine.- C. Some Properties of Selected Compounds.- I. Microtubular Inhibitors.- 1. Cytostatic Effects of Colchicine.- II. Cyclophosphamide.- 1. Metabolism.- 2. Properties of Some Metabolites.- 3. Site of Action.- 4. Some Side-Effects.- III. Chlorambucil.- 1. Metabolism.- 2. Anti-Inflammatory Effects.- 3. Mode of Action.- IV. Methotrexate.- V. Azathioprine.- D. Current Problems.- Appendix. Synovectomy and Destruction of Pannus.- References.- Addendum.- 36 Control of Hyperuricemia.- A. Introduction.- B. Uric Acid Metabolism.- C. Biochemical Pharmacology of Hypouricemic Drugs.- I. Drugs Reducing Uric Acid Synthesis.- 1. Allopurinol and Oxipurinol.- 2. Thiopurinol.- 3. Other Inhibitors of Uric Acid Synthesis.- II. Uricosuric Agents.- III. Uricolytic Agents.- D. Clinical Use of Hypouricemic Drugs.- I. Criteria for Selecting a Hypouricemic Drug.- II. Use of Individual Hypouricemic Drugs.- III. Toxicity of Hypouricemic Agents.- References.- 37 Anti-Inflammatory Steroids: Mode of Action in Rheumatoid Arthritis and Homograft Reaction.- A. General Considerations.- B. Scope of the Review.- C. Naturally Occurring Anti-Inflammatory Steroids.- D. Synthetic Anti-Inflammatory Steroids.- E. Biological Activities Observed With Physiological Amounts of Cortisol-Like Steroids.- I. Metabolic Effects.- 1. Gluconeogenesis.- 2. Protein Metabolism.- 3. DNA Synthesis.- 4. Molecular Basis for Metabolic Effects.- 5. Onset and Duration of Cortisol Action.- 6. Mechanism of Action of Cortisol.- 7. Glycogenosis.- 8. Lipolysis.- 9. Relationship to Anti-Inflammatory, Anti-Allergic and Anti-Rheumatic Action.- 10. Relationship to Clinically Undesirable Effects.- 11. Implications for the Future.- II. Sodium Retaining Activity.- III. Control of Adrenocorticotrophic Hormone (ACTH) Synthesis and Secretion.- 1. Neuroendocrine Control.- 2. Negative Feedback Control.- 3. Basis for Negative Feedback Control.- 4. Role of Cytoplasmic Steroid Receptors.- 5. Relationship to Clinically Desirable Effects.- 6. Relationship to Clinically Undesirable Effects.- IV. Cardiovascular Effects.- 1. Heart and Peripheral Blood Vessels in Adrenalectomised State.- 2. Microcirculation.- 3. Relationship to Anti-Inflammatory, Anti-Allergic, and Anti-Rheumatic Action.- 4. Relationship to Clinically Undesirable Effects.- 5. Pharmacological Implications.- F. Mode of Action in Homograft Reaction.- I. Interference With the Development of Circulating Sensitized Lymphocytes.- II. Effectiveness Against Inflammation Due to Locally Sensitized Lymphocytes.- III. Effectiveness Against Inflammation Due to Circulating Sensitized Lymphocytes.- IV. Clinical Relevance of Experimental Observations.- V. Relevance to Evaluation of More Effective Anti-Rejection and Anti-Rheumatic Drugs.- G. Concluding Remarks.- References.- 38 Anti-Inflammatory Agents of Animal Origin.- A. Introduction.- B. Definition and Evaluation of Anti-Inflammatory Activity.- C. Mechanisms of Action.- D. Individual Agents.- I. Alkoxyglyce

فهرست مطالب

Front Matter....Pages I-XXIX
Front Matter....Pages 1-1
Screening and Assessment of the Potency of Anti-Inflammatory Drugs in vitro....Pages 3-43
Inhibition of Erythema and Local Hyperthermia....Pages 44-74
Oedema and Increased Vascular Permeability....Pages 75-91
Short-Term Drug Control of Crystal-Induced Inflammation....Pages 92-107
Experimental Models of Arthritis in Animals as Screening Tests for Drugs to Treat Arthritis in Man....Pages 108-144
Antagonism of Bradykinin Bronchoconstriction by Anti-Inflammatory Drugs....Pages 145-163
Interference of Anti-Inflammatory Drugs with Hypotension....Pages 164-208
Antagonism of Pain and Hyperalgesia....Pages 209-222
Inhibition of Cell Migration in vivo and Granuloma Formation....Pages 223-254
Inhibition of Fever....Pages 255-279
Evaluation of the Toxicity of Anti-Inflammatory Drugs....Pages 280-302
Front Matter....Pages 303-303
Prostaglandin Synthetase Inhibitors I....Pages 305-347
Mode of Action of Anti-Inflammatory Agents Which are Prostaglandin Synthetase Inhibitors....Pages 348-398
Penicillamine and Drugs With a Specific Action in Rheumatoid Arthritis....Pages 399-414
Antagonists of Histamine, 5-Hydroxytryptamine and SRS-A....Pages 415-466
Inhibitors of the Release of Anaphylactic Mediators....Pages 467-530
Cytostats with Effects in Chronic Inflammation....Pages 531-578
Control of Hyperuricemia....Pages 579-597
Anti-Inflammatory Steroids: Mode of Action in Rheumatoid Arthritis and Homograft Reaction....Pages 598-660
Anti-Inflammatory Agents of Animal Origin....Pages 661-697
Front Matter....Pages 303-303
Anti-Inflammatory Substances of Plant Origin....Pages 698-739
A Critical Comparison of the Evaluation of Anti-Inflammatory Therapy in Animal Models and Man....Pages 740-766
Back Matter....Pages 767-954

نظرات کاربران

کتاب های تصادفی

دانلود کتاب كيف يجب علينا أن نفسر القرآن الكريم.

دانلود کتاب Kurze Anweisung zur Hausapotheke des Laien

دانلود کتاب Macroeconomic Analysis and Parametric Control of a National Economy

دانلود کتاب Influence Redefined: Be the Leader You Were Meant to Be, Monday to Monday

دانلود کتاب Историческая хронология